194394412 - 1_36ae7aui - PID 1851201
    
    
      
    
  

  
    
        Hi I am Ted Dixon with
        your INK Morning Report
Preview for
        October 27th: BioVaxys
insiders
        bet on the haptenization
of cancer and covid.
        We are doing a mini-series
this week on
        the Healthcare sector
which
        may be close to putting in
a bottom,
        at least based on
        our insider sentiment
signals.
        Today, we head into
        the traditional
biotechnology
        space and revisit
        Vancouver-based BioVaxys
        last featured here March
17th.
        Although recent insider
buying has
        been primarily through
        options and other means,
        the stock ranks high on
insider commitment.
        While the stock is down
since
        our March report,
technically,
        it appears to be back in
        an uptrend trading above
        both its 50-day and
200-day moving averages
        and is attempting to
over-take its 20-day.
        The stock hit a 52-week
high of 78 cents in
        February following
        the February 10th news
that Procare Health,
        a spin out of a Proctor &
Gamble division,
        would be collaborating
with
        BioVaxys in the
development of
        three key BioVaxys
        women’s health related
vaccines.
        In particular, the terms
of
        the agreement envision the
two parties
        jointly conducting
        a Phase I Clinical Study
in Spain of
        BioVaxys BVX- haptenized
protein vaccine
        for late-stage ovarian
cancer.
        The BioVaxys haptenized
vaccine platform
        is based on an approach
that teaches
        a patient's immune system
to recognize and
        target viral or tumor
antigens
        via haptenization.
        Antigen targets are
modified with
        a hapten chemical to make
the intruder more
        visible to immune system
with the objective
        of stimulating a robust
immune response.
        As we mentioned in our
March report,
        BioVaxys is also working
        on a COVID-19 vaccine.
        Although BioVaxys clearly
has
        a lot of work ahead,
        for risk-tolerant
biotechnology investors,
        the stock may provide
        an opportunity to bet on
        haptenization as a way to
potentially
        defeat some big biological
foes.
        That is all for today
        and thanks for stopping
by.
        Click on the notify button
        under this video on
        INK Ultra Money to be
notified when
        we have our next preview
available.
        Members can also find
        our full report under this
video.
        Finally, don’t forget to
        follow us on Twitter
@inkresearch.
        Join us again tomorrow as
we let
        the insiders guide us
        to opportunity this fall.
        This is not a
recommendation to
        buy or sell securities and
        nothing in this video or
        in INK reports should be
considered
        financial advice
information is for
        educational purposes INK
employees may
        hold an interest in any
stock
        mentioned in our videos or
in our reports.